Olfr583 Inhibitors
Olfr583, a member of the olfactory receptor family, plays a pivotal role in olfactory signal transduction, contributing to the detection and discrimination of specific odorants. Situated in the sensory neurons of the olfactory epithelium, Olfr583 functions as a molecular detector, initiating a cascade of intracellular events upon activation. Its primary responsibility lies in transmitting olfactory stimuli into neural signals, contributing to the complex and nuanced process of odor perception. The inhibition of Olfr583 involves a sophisticated interplay of various cellular pathways targeted by the presented indirect inhibitors. These chemicals modulate key signaling cascades such as EGFR, MAPK, TGF-β, PI3K/Akt/mTOR, NF-κB, and JNK. By disrupting these pathways, the inhibitors induce altered gene expression patterns of Olfr583, indirectly downregulating its activity. The intricate interplay between these pathways highlights the complexity of Olfr583 regulation, emphasizing the need for a comprehensive understanding of the molecular events governing olfactory signal transduction.
In summary, Olfr583 holds significance in the olfactory system, contributing to the intricate process of odor perception. The presented indirect inhibitors shed light on potential avenues for modulating Olfr583 expression by precisely targeting key cellular pathways associated with olfaction. This nuanced understanding enhances our comprehension of olfactory receptor regulation, providing insights into the complex mechanisms governing olfactory perception at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual EGFR/HER2 inhibitor that indirectly modulates Olfr583 expression by disrupting the EGFR signaling pathway. This inhibition occurs through interference with downstream cascades, leading to altered gene expression patterns of Olfr583. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib, a MEK inhibitor, indirectly influences Olfr583 by targeting the MAPK pathway. By disrupting the MEK-ERK signaling axis, Selumetinib leads to modified gene expression patterns, serving as an indirect inhibitor of Olfr583 through interference with its associated pathways. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $198.00 $650.00 | 16 | |
A83-01 acts as a TGF-β receptor inhibitor, indirectly inhibiting Olfr583 by attenuating downstream Smad signaling. This interference with the TGF-β pathway results in altered cellular responses, impacting Olfr583 expression through disruptions in the associated molecular cascades. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr583 by modulating the PI3K/Akt/mTOR pathway. This inhibition leads to altered intracellular signaling, impacting Olfr583 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus, an mTOR inhibitor, indirectly influences Olfr583 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr583 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr583 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr583 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr583 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr583 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Bay 11-7082, an NF-κB inhibitor, indirectly inhibits Olfr583 by modulating the NF-κB signaling pathway. This leads to altered cellular responses, affecting Olfr583 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr583 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, a MEK inhibitor, hinders the MAPK pathway, impacting Olfr583 indirectly. By disrupting the MEK-ERK signaling axis, U0126 leads to altered gene expression patterns, serving as an indirect inhibitor of Olfr583 through interference with its downstream pathways. | ||||||